1. Leadership Through Innovation Tm
Nevro

2. Nevro: Advancing Spinal Cord Stimulation
Novel Rechargeable Spinal Cord Stimulator
Implantable device placed minimally invasively by Pain Specialists and Spine Surgeons
Unique high-frequency waveform up to 10kHz
Anatomic lead placement without paresthesia mapping
The Senza® System is an investigational device in the U.S.

3. Company Milestones 2006 2007 2008 2009 2010 2011 2012 IDE initiated
US IP issued
European launch
International pivotal clinical
Pilot short term testing in US study
Early external prototype testing
Validation in additional large animal model:
UC Davis
Animal work: Stanford University
Founded at Mayo: Initial idea generation roundtable

4. US Senza-RCT Study Underway
Negotiated with the FDA
First study to compare SCS device systems
Non-inferiority study on safety and efficacy
Largest randomized SCS study ever conducted
Senza compared to commercially available SCS
The Senza® System is an investigational device in the U.S.

5. Safety and Effectiveness Endpoints
Primary
Non-inferiority comparison: change in back pain VAS and neurological status from baseline
Secondary
Assessments such as
% change in back pain, leg pain, function
Adverse event rates
Paresthesia perception
Tertiary
Includes sleep quality, quality of life, depression level, pain med usage
The Senza® System is an investigational device in the U.S.

6. Pain Gaining Recognition as a Challenge

7. Opportunity for SCS Community
Expansion
Opportunity
Physical therapy & conservative therapies
Interventional techniques (i.e. blocks)
Spine surgery
Oral
opioids
Spinal cord stimulation
Drug
Pumps

8. Difficult Funding Environment for Innovation

9. Opportunity for Neuromodulation
Significant opportunity for neuromodulation to improve healthcare
To accomplish this, additional effort needed in:
Clinical Evidence
Education for HCP and Payers
Patient Experience